STAT3 and cancer: Considering the facts that both STAT3 and Akt are critical kinases for the self-renewal and pluripotency of the cancer stem cells [37, 38], it is plausible to combine gefitinib with agents that target STAT3 and Akt to prevent gefitinib resistance and the faster relapse of the tumors.